Evidence map›Paper›PMID 29860581›Full record

ReviewChinese journal of integrative medicine2018

Research Progress on Reversing Multidrug Resistance in Tumors by Using Chinese Medicine.

Huan-Dong Zhao, Hong-Juan Xie, Jian Li, Cai-Ping Ren, Yu-Xiang Chen

Abstract readReview
PubMed Publisher
In one paragraph

Review in Chinese journal of integrative medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Active Ingredients from Chinese Medicine for Combination Cancer Therapy.International journal of biological sciences · 2023
    Review
  2. Review
  3. Combating Drug Resistance in Colorectal Cancer Using Herbal Medicines.Chinese journal of integrative medicine · 2021
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Evidence-based complementary and alternative medicine : eCAM · 2018
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huan-Dong ZhaoKey Laboratory of Nanobiological Technology of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, 410008, China.
Hong-Juan XieDepartment of Pharmacy, Tongren Hospital, Shanghai Jiaotong University, School of Medicine, Shanghai, 200336, China.
Jian LiKey Laboratory of Nanobiological Technology of Chinese Ministry of Health, Xiangya Hospital, Central South University, Changsha, 410008, China.
Cai-Ping RenCancer Research Institute, Collaborative Innovation Center for Cancer Medicine, Key Laboratory for Carcinogenesis of Chinese Ministry of Health, School of Basic Medical Science, Central South University, Changsha, 410078, China.
Yu-Xiang ChenSchool of Pharmacy, Central South University, Changsha, 410013, China. Chenyx008@aliyun.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multidrug resistance (MDR) is a major cause of cancer chemotherapy failure, and it is important to develop suitable reversal agents to overcome MDR. A majority of chemical reversal agents have acceptable reversal effects. However, the toxicity and adverse reactions associated with these agents restricts their clinical use. Chinese medicines (CMs) have lower toxicities and adverse reactions and are associated with multiple components, multiple targets and reduced toxicity. CMs have several advantages and could reverse MDR, decrease drug dosage, enhance patient compliance and increase efficacy. This review summarizes the current progress of CM reversal agents..

Indexed as

ResearchDrug Resistance, MultipleDrug Resistance, NeoplasmDrugs, Chinese HerbalHumansPlant ExtractsDrugs, Chinese HerbalPlant ExtractsChinese medicinemultidrug resistancereversal agentstumor

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.